about
Solution Structure of LC4 Transmembrane Segment of CCR5Functional reconstitution of the human chemokine receptor CXCR4 with G(i)/G (o)-proteins in Sf9 insect cellsTropism testing in the clinical management of HIV-1 infection.Analytical and biological considerations in the measurement of cell-associated CCR5 and CXCR4 mRNA and proteinStructural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.Small molecule inhibitors of CXCR4.A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.Persistence and emergence of X4 virus in HIV infection.Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transductionTargeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acidsHIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drugDifferential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitorsStable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates.Establishment of HIV-1 model cell line GHOST(3) with stable DRiP78 and NHERF1 knockdown.Role of integrase inhibitors in the treatment of HIV disease.Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.Recent progress in antiretrovirals--lessons from resistanceTopical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.Maraviroc: a new CCR5 antagonist.Chemokines, chemokine receptors and CD4+CD25+ regulatory T cells.Pharmacological modulation of chemokine receptor function.Drug resistance in HIV-1.Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells.Biological and Structural Characterization of Rotamers of C-C Chemokine Receptor Type 5 (CCR5) Inhibitor GSK214096.
P2860
Q27666261-5B814A58-E946-4130-93E9-C43B12D4DC00Q30438828-A7DB1E0E-AAA8-479D-9445-61E3F82B9BF4Q33869686-73B7900A-878F-4CD2-AF62-F1E3F79E6D47Q33962644-84FC873D-41BF-485D-AD7B-30F1323108E4Q34064787-00E1465E-55C1-4B1F-8CCB-C0EF16F79EC4Q34481372-03702C27-CE97-408D-BE10-46DEDCD1F589Q34574987-06ECD42A-C2D6-4415-B495-0C4DB47107A4Q34606129-344C53CA-DBF5-4730-8C5A-C03F289A8ECCQ34757951-2308454D-F57A-4613-9ADE-69A88A40D3CAQ35055322-F7482E51-8B6B-4812-9F8A-599A54CF7EC0Q35122039-F357C15A-A93C-405F-9FD7-F2F76F508834Q35244141-4F49290A-0D2F-4657-BD74-4A756E33E3B3Q35665842-06017C59-1688-42E1-8488-5071D3A63EFFQ35867443-FCA7A1B9-7F00-4566-BDA6-E34CF1169F38Q35904711-0EEAE7D2-7DF0-4803-B6EB-58C2007A12C3Q35928777-82BAC8FB-C164-4A84-9CBF-FB6FFB1C86DBQ36684295-5AFFEE6C-20B2-409F-A41F-32C326AD5DAFQ36723801-D425D31B-B498-4AF8-B4E9-BB00ADC61A8BQ36839845-06411E17-8F87-452C-8A4E-867BF4F5F3A8Q36967857-90692844-9262-49DF-8D6F-277BD3E2DDCBQ37088591-D13DA564-0D71-4E9E-B6E1-82FCCFB5A0DDQ37145319-0E2C83BB-6CAF-44CA-BCAD-03C03659016FQ37557671-35AF11E9-AA01-411E-9E97-F99447B33D31Q37755313-4664220D-2DE3-48C9-BBFC-E528BF476BA9Q37893687-C0235EB6-B3D2-40E0-8A65-F80FD45D6393Q37967710-880DDB75-9080-4275-9CA6-2F3ABD14410DQ39433148-C1D011CA-0655-406F-90EC-DC1C45F8082DQ39600778-B921AA5E-6BB6-4E7A-BEBE-987DC973D19DQ39682767-9FD6A4C1-C7EE-4669-ACCC-62F9AD41B82AQ41595129-A57C6F1B-C82E-4E97-AFB1-E71216A5803E
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Chemokine antagonists as therapeutics: focus on HIV-1.
@ast
Chemokine antagonists as therapeutics: focus on HIV-1.
@en
type
label
Chemokine antagonists as therapeutics: focus on HIV-1.
@ast
Chemokine antagonists as therapeutics: focus on HIV-1.
@en
prefLabel
Chemokine antagonists as therapeutics: focus on HIV-1.
@ast
Chemokine antagonists as therapeutics: focus on HIV-1.
@en
P1476
Chemokine antagonists as therapeutics: focus on HIV-1.
@en
P2093
Athe M N Tsibris
Daniel R Kuritzkes
P304
P356
10.1146/ANNUREV.MED.58.080105.102908
P577
2007-01-01T00:00:00Z